6 weeks of treatment with adalimumab (40 mg every 2 wk) and a tapering dose of deflazacort. Versini et al.\(^6\) described the case of a patient with SPD and MGUS who was refractory to multiple treatments, including infliximab and etanercept. Complete lesion clearance was observed after 5 months of adalimumab therapy (induction dose, 80 mg at wk 0 and 40 mg at wk 1; maintenance dose, 40 mg every 2 wk).

To our knowledge this is the first published report of a good response to adalimumab in a patient with concomitant PG and SPD. This drug is a potential therapeutic alternative for the treatment of ND refractory to other agents, and can provide rapid lesion improvement and control of recurrences.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### References


M.C. García del Pozo-Martin de Hijas,\(^*\) J.L. Agudo-Mena, M.E. Gómez-Sánchez, E. Escario-Travesedo

**Servicio de Dermatología Médico-Quirúrgica y Venereología, Complejo Hospitalario Universitario de Albacete, Albacete, Spain**

\(^*\) Corresponding author.

**E-mail address:** magarciaadel@sescam.jccm.es

(M.C. García del Pozo-Martin de Hijas).

8 January 2019 26 February 2019

https://doi.org/10.1016/j.adengl.2020.01.018

1578-2190/ © 2020 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

---

**Treatment of 2 Patients With Aquagenic Pruritus With UVA/Narrow Band UVB Combined Therapy Once a Year**\(^\dagger\)

**Tratamiento de 2 pacientes con prurito acuagénico con ciclos de terapia combinada UVA/UVB de banda estrecha una vez por año**

**To the Editor:**

Aquagenic pruritus (AP) is characterized by the onset of pruritus after contact with water, with no evident skin lesions unlike aquagenic urticaria. It is an uncommon condition in Spain, but it can affect up to 20% of young adults in African countries.\(^1\) The disease may have a major negative impact on quality of life\(^1\) and management is difficult.\(^2,3\) One of the most effective treatments is phototherapy, but relapses are frequent and maintenance therapy is required.\(^4\) Cases have been reported in which an annual cycle of UVA and narrow-band UVB combination therapy (UVA/NB-UVB CT) achieved good outcomes.\(^5,6\) Our objective was to assess response to annual cycles of UVA/NB-UVB CT in patients with AP refractory to antihistamine agents.

Long-term clinical response was retrospectively analyzed in patients with AP refractory to high doses of antihistamine agents treated with UVA/NB-UVB CT in a reference hospital in Barcelona, Spain, between January 2010 and January 2019. Two women aged 52 and 31 years were identified. The case of patient 1 had been reported previously;\(^6\) her mother also had AP. Patient 2 had celiac disease. In both cases, symptoms had presented more than 5 years previously and the patients had received multiple treatments (Table 1).

---

\(^\dagger\) Please cite this article as: Morgado-Carrasco D, Riera-Monroig J, Feola H, Aguilara P. Tratamiento de 2 pacientes con prurito acuagénico con ciclos de terapia combinada UVA/UVB de banda estrecha una vez por año. Actas Dermosifiliogr. 2020;111:889–892.
### Table 1  Clinical and Epidemiological Characteristics and Therapeutic Response of Patients With Aquagenic Pruritus in UVA and Narrow-Band UVB Combination Therapy.

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex/Age, y</th>
<th>Comorbidities</th>
<th>Family History</th>
<th>Duration of Symptoms</th>
<th>Prior Treatments</th>
<th>UVA/NB-UVB CT Induction Dose</th>
<th>Number of Sessions</th>
<th>Maximum Dose</th>
<th>Total Number of Cycles of UVA/NB-UVB CT</th>
<th>Clinical Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F/52</td>
<td>No</td>
<td>Yes, mother with aquagenic pruritus</td>
<td>&gt; 5 years</td>
<td>Antihistamines, montelukast, beta-carotene</td>
<td>4 J/cm^2 (UVA) and 200 mJ/cm^2 (NB-UVB)</td>
<td>17 to 26/year</td>
<td>9 J/cm^2</td>
<td>4</td>
<td>Complete</td>
</tr>
<tr>
<td>2</td>
<td>F/31</td>
<td>Celiac disease</td>
<td>No</td>
<td>&gt; 5 years</td>
<td>Antihistamines, montelukast</td>
<td>4 J/cm^2 (UVA) and 200 mJ/cm^2 (NB-UVB)</td>
<td>36</td>
<td>5 J/cm^2</td>
<td>1</td>
<td>No clinical response</td>
</tr>
</tbody>
</table>

Abbreviations: F, female; NB UVB, narrow-band UVB; UVA/NB-UVB CT, UVA/narrow-band UVB combined therapy.

a The maximum dose of UVA was 9 J/cm^2 the first year, and in the following cycles, it did not exceed 5 J/cm^2. The total dose after 4 cycles of UVA/NB-UVB CT was 266.5 J/cm^2 (UVA) and 89.6 J/cm^2 (NB-UVB).

b Patient 2 discontinued phototherapy after 36 sessions and has not repeated treatment.
Laboratory tests (hemogram, erythrocyte sedimentation rate, creatinine levels, liver and lipid profile) were normal in both patients, except for a small increase in IgE. They were treated with UVA/NB-UVB CT 3 times a week (17–34 sessions a year). The starting doses were 4 J/cm² (UVA) and 200 mJ/cm² (NB-UVB). The maximum doses were 9 J/cm² (UVA) and 1.2 J/cm² (NB-UVB) (Table 1). Patient 1 presented complete and prolonged response, remaining free of symptoms for more than 5 years with an annual cycle of UVA/NB-UVB CT (17–26 sessions before the beginning of the summer, 4 cycles in total). The second patient completed 36 sessions of UVA/NB-UVB CT during the first year, with no clinical improvement, and so phototherapy was discontinued.

**Discussion**

AP is generally idiopathic, although up to 30% of cases have been associated with hematological conditions such as polycythemia vera or myelodysplasia, and 25% of cases may be associated with lactose intolerance. Other known associations include neoplasms, hepatitis C, and drugs such as bupropion and antimalarial agents. Idiopathic AP occurs more frequently in young women and has a longer duration than AP with a known cause. AP may seriously impact activities of daily living; it has been reported that up to 8% of patients may develop phobia of washing. One of our patients avoided getting her legs wet for fear of triggering pruritus and burning sensation. The pathophysiology of AP is not fully understood, although it is thought there is increased skin innervation with dysfunctional and hyperexcitable C-nerve fibers, probably caused by defective sodium channels. The role of histamine is minimal, thus explaining the limited response to antihistamine agents. Treatment of AP is complex and, often, outcomes are disappointing for both the physician and the patient. Different topical treatments have been used such as increasing the pH of water with sodium bicarbonate, capsaicin, and glycerol trinitrate. Oral drugs such as antihistamine agents, pregabalin, acetylsalicylic acid, beta blockers (propranolol, atenolol), and antidepressants, among others have been tried (Table 2). There have also been reports of patients treated with interferon and omalizumab. Phototherapy is one of the most effective treatment modalities, including psoralene plus UVA (PUVA) and UVB. However, this is not curative and requires maintenance therapy to achieve symptomatic remission. This can be problematic with PUVA, given its carcinogenic potential. NB-UVB has a better safety profile, but evidence for its use in AP is very limited, with only 3 case reports available. In all cases, it was effective in inducing remission. In 2 patients, a weekly dose was required to maintain clinical response for 4 and 6 months, respectively. This regimen is associated with substantial logistic issues and expense. The third patient relapsed after suspending phototherapy and this was discontinued; propranolol was initiated with good response. Including our patients, there are 3 cases reported of treatment with UVA/NB-UVB CT in which an annual cycle is used as maintenance therapy, with excellent response in 2 of them while 1 case was refractory. Phototherapy probably

**Table 2** Drugs and Different Agents Used in the Treatment of Aquagenic Pruritus.

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Topical</strong></td>
<td>Increased bath pH (pH 8) with sodium bicarbonate (0.1–0.6 kg/bath)</td>
</tr>
<tr>
<td>Capsaicin (0.025% to 1% 3 times a day for 4 weeks)</td>
<td></td>
</tr>
<tr>
<td>Glycerol trinitrate 2% gel</td>
<td></td>
</tr>
<tr>
<td>Transdermal scopolamine 3% or 9% in water, acetone, or ethanol before bathing</td>
<td></td>
</tr>
<tr>
<td><strong>Oral</strong></td>
<td>Antihistamines (hydroxyzine, astemizole, chlorpheniramine, cetirizine, loratadine, fexofenadine, terfenadine)</td>
</tr>
<tr>
<td>H2 blockers (cimetidine 900 mg/d)</td>
<td></td>
</tr>
<tr>
<td>Acetylsalicylic acid 300–500 mg/d</td>
<td></td>
</tr>
<tr>
<td>Pregabalin 150–300 mg/d</td>
<td></td>
</tr>
<tr>
<td>Opioid receptor antagonists (naltrexone 25–50 mg/d)</td>
<td></td>
</tr>
<tr>
<td>Serotonin reuptake inhibitors (paroxetine 20 mg/d, fluoxetine 10 mg/d)</td>
<td></td>
</tr>
<tr>
<td>Interferon-α 2b (week 1: 5 × 3 thousand IU, week 2–4: 3 × 3 thousand IU)</td>
<td></td>
</tr>
<tr>
<td>Beta blockers (propranolol 10 mg/d, 20–30 min before bathing, or 60 mg/d and atenolol 25 mg/d)</td>
<td></td>
</tr>
<tr>
<td>Cholestyramine</td>
<td></td>
</tr>
<tr>
<td>Montelukast</td>
<td></td>
</tr>
<tr>
<td><strong>Intramuscular</strong></td>
<td>Triamcinolone</td>
</tr>
<tr>
<td><strong>Subcutaneous</strong></td>
<td>Omalizumab (300 mg every 4 weeks)</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td>Transcutaneous electrical nerve stimulation</td>
</tr>
<tr>
<td>Use of tight-fitting Lycra clothing</td>
<td></td>
</tr>
<tr>
<td><strong>Phototherapy</strong></td>
<td>PUVA</td>
</tr>
<tr>
<td>UVB</td>
<td></td>
</tr>
<tr>
<td>NB-UVB</td>
<td></td>
</tr>
<tr>
<td>UVA/NB-UVB CT</td>
<td></td>
</tr>
</tbody>
</table>

Source: Heitkemper et al.; Cao et al.; Murphy et al.
Abbreviations: UVA/NB-UVB CT, UVA/narrow-band UVB combined therapy; NB UVB, narrow band UVB; PUVA, psoralene with UVA.
acts as a neuromodulator, reducing the density of skin nerve fibers and levels of neural growth factors,\(^1\) in addition to its well-established immunomodulatory effect.

Treatment of AP is difficult. We have reported a new case of treatment with UVA/NB-UVB CT, without clinical response, and long-term follow-up of a female patient treated for more than 5 years (4 cycles of UVA/NB-UVB CT) with complete remission of symptoms. Cycles of UVA/NB-UVB CT once a year may be a good alternative for long-term management of some patients with refractory AP.

**Funding**

This study did not receive any funding.

**Conflicts of interest**

The authors declare that they have no conflicts of interest.

**References**


D. Morgado-Carrasco, J. Riera-Monroig, H. Feola, P. Aguilera

Dermatology Department, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain

*Corresponding author.

E-mail address: morgadodaniel8@gmail.com

(D. Morgado-Carrasco).

4 February 2019 17 February 2019

https://doi.org/10.1016/j.adengl.2019.02.027

Whitish Dots Provide the Key to Diagnosing Condyloma Lata: A Report of 5 Cases\(^1\)

**Puntos blanquecinos como clave diagnóstica de condilomas planos: reporte de 5 casos**

**To the Editor:**

Syphilis, traditionally known as the great imitator remains among us and requires maintaining a high level of diagnostic suspicion. As well as its usual forms of clinical presentation, extremely rare skin manifestations may appear that sometimes make diagnosing this entity difficult.\(^2\) Condyloma lata (CL) is a classic, though rare, cutaneous manifestation of secondary syphilis.\(^2\) The increased incidence of syphilis may lead to an increase in the number of cases with atypical presentation,\(^1\) such as those we describe below.

In this study, we collected all the cases of CL diagnosed in the STI unit of the dermatology department of Hospi-

tal General de Valencia, Valencia, Spain, between January 2015 and January 2019. In this period, a total of 95 cases were diagnosed, 49.5% of which (47 cases) were secondary syphilis. Of these, 11 cases (21.4%) showed CL in the anogenital region. We found CL with white spots on the surface in only 5 patients diagnosed with syphilis in this time. The characteristics of these patients are shown in Table 1.

In the physical examination, the 5 patients presented a notable lesion in the perianal region (Fig. 1). This lesion was raised, with pink fleshy edges surrounding a friable erythematous center with characteristic white spots on the surface. Dermoscopy revealed a lesion with milky-red areas in the center and well-defined pearly globules in the center (Fig. 2A). In Case 1, this lesion was the patient’s only clinical sign. In Cases 3 and 4, this lesion was accompanied by perianal condylomata acuminata (CA).

Biopsies were performed in 2 of the cases to confirm the diagnosis of CL. The characteristics of both samples are very similar, with a psoriasiform hyperplasia of the epidermis with marked exocytosis and formation of spongiform pustules, accompanied by a dense lymphoplasmacytic dermal infiltrate (Fig. 2B-D). Immune staining with anti-Treponema pallidum antibodies was positive in both patients.

In the 2 patients with suspected coinfection with the human papillomavirus (HPV), samples were taken for histopathology and genotyping of the virus. One of the patients developed epidermoid carcinoma of the anal canal.

---

\(^1\) Please cite this article as: Magdaleno-Tapia J, Hernández-Bel P, Valenzuela-Oñate C, Alegre-de Miquel V. Puntos blanquecinos como clave diagnóstica de condilomas planos: reporte de 5 casos. Actas Dermosifiliogr. 2020;111:892–895.